Tacrolimus-induced interstitial lung injury in a pediatric cardiac transplant recipient: a case report and literature review

他克莫司诱发儿童心脏移植受者间质性肺损伤:病例报告及文献综述

阅读:2

Abstract

BACKGROUND: Tacrolimus-induced interstitial lung injury (TI-ILI) is a rare but potentially fatal adverse effect of calcineurin-inhibitor therapy. To our knowledge, TI-ILI has not previously been reported in a paediatric heart-transplant recipient. CASE PRESENTATION: A 6-year-old boy with PLN-related dilated cardiomyopathy underwent orthotopic heart transplantation. Maintenance immunosuppression comprised tacrolimus, mycophenolate mofetil and prednisone. On post-operative day 13 he developed bilateral ground-glass opacities with interlobular septal thickening on chest CT. Broncho-alveolar lavage metagenomics showed only low-abundance Pseudomonas aeruginosa and Acinetobacter baumannii; extensive microbiological, cardiac work-up was negative. Infiltrates progressed despite targeted antibiotics, but resolved within 4 weeks after tacrolimus was replaced by cyclosporine and corticosteroids were doubled. No relapse occurred during 6 months of follow-up. CONCLUSIONS: TI-ILI should be considered in any heart transplant recipient with unexplained progressive bilateral pulmonary infiltrates. Early tacrolimus withdrawal and prompt corticosteroid therapy are associated with complete recovery; re-exposure to tacrolimus is contraindicated.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。